Evidence map›Paper›PMID 42742915›Full record

ReviewTherapeutic innovation & regulatory science2026

Regulatory Reliance in Latin America: Opportunities and Implementation Challenges for International Pharmaceutical Companies.

Esteban Ortiz-Prado, Jorge Vasconez-Gonzalez, Dina Albuja Tapia, Diana Dominguez, Paola Edith Hernández-Montenegro, Stefanie B Samaniego-Cameron, Juan S Izquierdo-Condoy

Abstract readReview
PubMed Publisher
In one paragraph

Review in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Esteban Ortiz-PradoOne Health Research Group, Universidad de Las Américas, Avenida de los Granados, Via a Nayon, S/N, UDLA Park, Quito, 170516, Ecuador. e.ortizprado@gmail.com.
Jorge Vasconez-GonzalezOne Health Research Group, Universidad de Las Américas, Avenida de los Granados, Via a Nayon, S/N, UDLA Park, Quito, 170516, Ecuador.
Dina Albuja TapiaDepartamento de Ingeniería Química, Escuela Politécnica Nacional, Quito, Ecuador.
Diana DominguezOne Health Research Group, Universidad de Las Américas, Avenida de los Granados, Via a Nayon, S/N, UDLA Park, Quito, 170516, Ecuador.
Paola Edith Hernández-MontenegroDepartamento de Regulación, Ministerio de Salud Pública, Quito, Ecuador.
Stefanie B Samaniego-CameronOne Health Research Group, Universidad de Las Américas, Avenida de los Granados, Via a Nayon, S/N, UDLA Park, Quito, 170516, Ecuador.
Juan S Izquierdo-CondoyOne Health Research Group, Universidad de Las Américas, Avenida de los Granados, Via a Nayon, S/N, UDLA Park, Quito, 170516, Ecuador.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory reliance is increasingly used to reduce unnecessary duplication in pharmaceutical regulation, but its legal basis, operational depth, and effect on review time vary substantially across Latin America. This structured narrative policy and practice review maps publicly documented reliance, recognition, verification, abridged/optimized review, homologation, and related facilitated pathways for human medicinal products in selected Latin American jurisdictions. Primary legal instruments and national regulatory authority (NRA) guidance were prioritized, supplemented by WHO/PAHO frameworks, peer-reviewed literature, and selected specialist regulatory sources. Extracted domains included the existence of a written legal or policy basis, pathway status, product eligibility, reference-authority criteria, product-sameness requirements, use of reference-agency assessment reports, local quality/safety/efficacy review, CPP and GMP requirements, pharmacovigilance obligations, and standard versus reliance-specific timelines. The evidence shows marked heterogeneity: some jurisdictions have formal, product-specific reliance procedures, whereas others use partial mechanisms, regional mutual-recognition arrangements, or pathways that remain under implementation. Publicly available reliance-specific review times are sparse and are rarely stratified by new active substances, generics, biosimilars, biologics, or vaccines; therefore, observed or reported timelines should not be interpreted as a uniform causal effect of reliance. For international pharmaceutical sponsors, prior approval by a trusted authority may support a facilitated pathway only when the receiving NRA's legal basis, product scope, dossier sameness, documentary requirements, and post-market obligations are satisfied. Greater transparency on review depth, assessment-report access, and product-level performance metrics is needed to determine the real-world impact of regulatory reliance in the region.

Indexed as

International pharmaceutical companiesLatin AmericaMarket accessPharmaceutical regulationRegulatory relianceWHO-Listed Authorities

Identifiers

PMID42742915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.